Wall Street brokerages expect Marchex, Inc. (NASDAQ:MCHX) to announce sales of $18.23 million for the current quarter, according to Zacks. Two analysts have made estimates for Marchex’s earnings. The highest sales estimate is $21.16 million and the lowest is $15.30 million. Marchex posted sales of $26.34 million during the same quarter last year, which indicates a negative year-over-year growth rate of 30.8%. The firm is expected to issue its next earnings report on Wednesday, August 5th.
According to Zacks, analysts expect that Marchex will report full year sales of $87.04 million for the current financial year, with estimates ranging from $84.40 million to $89.67 million. For the next year, analysts expect that the business will report sales of $93.10 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Marchex.
Marchex (NASDAQ:MCHX) last released its quarterly earnings results on Monday, May 11th. The technology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.03). Marchex had a negative return on equity of 5.36% and a negative net margin of 26.43%. The firm had revenue of $24.79 million for the quarter, compared to analysts’ expectations of $23.31 million.
Hedge funds have recently bought and sold shares of the company. Jefferies Group LLC acquired a new stake in shares of Marchex during the 4th quarter valued at approximately $41,000. Marshall Wace LLP acquired a new position in shares of Marchex during the 4th quarter worth approximately $59,000. Barclays PLC raised its position in shares of Marchex by 100.9% during the 4th quarter. Barclays PLC now owns 36,588 shares of the technology company’s stock worth $139,000 after purchasing an additional 18,378 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Marchex by 17.4% during the 1st quarter. Wells Fargo & Company MN now owns 98,541 shares of the technology company’s stock worth $143,000 after purchasing an additional 14,624 shares during the last quarter. Finally, UBS Group AG raised its position in shares of Marchex by 69.5% during the 4th quarter. UBS Group AG now owns 46,792 shares of the technology company’s stock worth $177,000 after purchasing an additional 19,186 shares during the last quarter. Institutional investors own 65.60% of the company’s stock.
Shares of MCHX traded up $0.02 during midday trading on Monday, hitting $1.52. 322,492 shares of the stock were exchanged, compared to its average volume of 243,734. Marchex has a 52-week low of $1.10 and a 52-week high of $4.98. The stock has a fifty day simple moving average of $1.54 and a 200 day simple moving average of $2.43. The firm has a market cap of $66.63 million, a P/E ratio of -2.63 and a beta of 1.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.25 and a current ratio of 3.25.
Marchex, Inc operates as a call analytics company that helps businesses connect, drive, measure, and convert callers into customers. Its products include Marchex Call Analytics, an analytics platform for enterprises that depend on inbound phone calls to drive sales, appointments, and reservations; Marchex Speech Analytics that enable actionable insights for enterprise, mid-sized, and small businesses; Text Analytics and Communications, which enable businesses to send and receive text/SMS messages with customers; Call Monitoring; Marchex Omnichannel Analytics Cloud products, such as Marchex Search Analytics, a product for search marketers that drive phone calls from search campaigns, as well as Marchex Display and Video Analytics, a product for marketers that buy digital display advertising; Marchex Site Analytics, a product for marketers that can drive phone calls from Websites; and Marchex Social Analytics, a product for marketers that buy social media advertising.
Further Reading: Gap Down Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marchex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marchex and related companies with MarketBeat.com's FREE daily email newsletter.